US AI-enabled biotech Recursion (Nasdaq: RXRX) and UK-based Exscientia (Nasdaq: EXAI) today announced the companies have entered into a definitive merger agreement.
Exscientia shares leapt 18% to $5.24 while Recursion stock added a more modest rise of 5.4% to $6.71 on the news.
In an all-stock transaction reportedly valued at $688 million, the new company will bring together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform, with a commitment to create more effective medicines for patients, faster.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze